China's first independent research and development of human-derived anti-CD25 monoclonal antibody issued the first prescription

Kidney transplantation, as the most ideal kidney replacement therapy for patients with end-stage chronic renal failure, is rapidly being promoted worldwideChina's kidney transplant ational scientific registration system data center statistics show that in 2015, China completed a total of 7131 kidney transplants, after the United States ranked second in the worldHowever, the long-term survival rate of transplants after kidney transplantation has been lowAccording to the latest OPTN/SRTR annual report published in February 2019 in Am J Transplant, the 10-year total-cause transplant failure rate is 49.7%, meaning only 50.3% of the 10-year transplant survival ratethe application of immunosuppressants is very important in order to improve the long-term survival rate of the graftClinical applications have shown that antibody-induced therapy can reduce acute rejection and reduce the incidence of acute rejection in early postoperative times by 30%-40%In recent years, the choice of reasonable immunosuppressant program to reduce the incidence of adverse reactions and improve the long-term survival of kidney transplant patients has become a new trend, and humanized antibodies with fewer heterogeneous proteins are the needs of organ transplantation development in ChinaJune 2019, the first humanized anti-CD25 monoclonal antibody Kennito, independently developed by Sansheng Guojian, obtained the drug GMP certificate from the State Drug Administration to prevent acute rejection reactions caused by kidney transplantation, which can be combined with conventional immunosuppressive programs, significantly improve the survival rate of transplanted organs and improve the quality of patient sexistNote: Cut in the original text